132 related articles for article (PubMed ID: 26951145)
1. Integrated In Silico-In Vitro Discovery of Lung Cancer-related Tumor Pyruvate Kinase M2 (PKM2) Inhibitors.
Ye X; Sun Y; Xu Y; Chen Z; Lu S
Med Chem; 2016; 12(7):613-620. PubMed ID: 26951145
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase.
Ning X; Qi H; Li R; Li Y; Jin Y; McNutt MA; Liu J; Yin Y
Eur J Med Chem; 2017 Sep; 138():343-352. PubMed ID: 28688274
[TBL] [Abstract][Full Text] [Related]
3. In silico investigation of potential pyruvate kinase M2 regulators from traditional Chinese medicine against cancers.
Chen KC; Chen KB; Chen HY; Chen CY
Biomed Res Int; 2014; 2014():189495. PubMed ID: 25089263
[TBL] [Abstract][Full Text] [Related]
4. Identification of a new pyruvate kinase M2 isoform (PKM2) activator for the treatment of non-small-cell lung cancer (NSCLC).
Li RZ; Fan XX; Shi DF; Zhu GY; Wang YW; Luo LX; Pan HD; Yao XJ; Leung EL; Liu L
Chem Biol Drug Des; 2018 Nov; 92(5):1851-1858. PubMed ID: 29931766
[TBL] [Abstract][Full Text] [Related]
5.
Rasul A; Riaz A; Wei W; Sarfraz I; Hassan M; Li J; Asif F; Adem Ş; Bukhari SA; Asrar M; Li X
Biomed Res Int; 2021; 2021():5514669. PubMed ID: 34136566
[TBL] [Abstract][Full Text] [Related]
6. Roadmap to Pyruvate Kinase M2 Modulation - A Computational Chronicle.
Kapoor S; Chatterjee DR; Chowdhury MG; Das R; Shard A
Curr Drug Targets; 2023; 24(6):464-483. PubMed ID: 36998144
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic and Structural Insights into Cysteine-Mediated Inhibition of Pyruvate Kinase Muscle Isoform 2.
Srivastava D; Nandi S; Dey M
Biochemistry; 2019 Sep; 58(35):3669-3682. PubMed ID: 31386812
[TBL] [Abstract][Full Text] [Related]
8. PKM2 Thr454 phosphorylation increases its nuclear translocation and promotes xenograft tumor growth in A549 human lung cancer cells.
Yu Z; Huang L; Qiao P; Jiang A; Wang L; Yang T; Tang S; Zhang W; Ren C
Biochem Biophys Res Commun; 2016 May; 473(4):953-958. PubMed ID: 27045080
[TBL] [Abstract][Full Text] [Related]
9. Combining structure-based pharmacophore modeling, virtual screening, and in silico ADMET analysis to discover novel tetrahydro-quinoline based pyruvate kinase isozyme M2 activators with antitumor activity.
Chen C; Wang T; Wu F; Huang W; He G; Ouyang L; Xiang M; Peng C; Jiang Q
Drug Des Devel Ther; 2014; 8():1195-210. PubMed ID: 25214764
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and structural insights into how amino acids regulate pyruvate kinase muscle isoform 2.
Nandi S; Dey M
J Biol Chem; 2020 Apr; 295(16):5390-5403. PubMed ID: 32144209
[TBL] [Abstract][Full Text] [Related]
11. A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
Arora S; Joshi G; Chaturvedi A; Heuser M; Patil S; Kumar R
J Med Chem; 2022 Jan; 65(2):1171-1205. PubMed ID: 34726055
[TBL] [Abstract][Full Text] [Related]
12. Tumor M2-PK: A novel urine marker of bladder cancer.
Liu W; Woolbright BL; Pirani K; Didde R; Abbott E; Kaushik G; Martin P; Hamilton-Reeves J; Taylor JA; Holzbeierlein JM; Anant S; Lee EK
PLoS One; 2019; 14(6):e0218737. PubMed ID: 31246990
[TBL] [Abstract][Full Text] [Related]
13. Structure-Guided Approach to Discover Tuberosin as a Potent Activator of Pyruvate Kinase M2, Targeting Cancer Therapy.
Adnan M; Shamsi A; Elasbali AM; Siddiqui AJ; Patel M; Alshammari N; Alharethi SH; Alhassan HH; Bardakci F; Hassan MI
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361954
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of the M2 Isoform of Pyruvate Kinase (PKM2) with shRNA Enhances the Effect of Docetaxel in Human NSCLC Cell Lines In Vitro.
Yuan S; Qiao T; Zhuang X; Chen W; Xing N; Zhang Q
Yonsei Med J; 2016 Nov; 57(6):1312-23. PubMed ID: 27593857
[TBL] [Abstract][Full Text] [Related]
15. Vitamin K(3) and K(5) are inhibitors of tumor pyruvate kinase M2.
Chen J; Jiang Z; Wang B; Wang Y; Hu X
Cancer Lett; 2012 Mar; 316(2):204-10. PubMed ID: 22154083
[TBL] [Abstract][Full Text] [Related]
16. High-throughput screening against ~6.1 million structurally diverse, lead-like compounds to discover novel ROCK inhibitors for cerebral injury recovery.
Gong H; Yuan Z; Zhan L
Mol Divers; 2016 May; 20(2):537-49. PubMed ID: 26700101
[TBL] [Abstract][Full Text] [Related]
17. Identification of Natural Compounds as Inhibitors of Pyruvate Kinase M2 for Cancer Treatment.
Sarfraz I; Rasul A; Jabeen F; Sultana T; Adem Ş
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296707
[TBL] [Abstract][Full Text] [Related]
18. Discovery of boronic acid-based potent activators of tumor pyruvate kinase M2 and development of gastroretentive nanoformulation for oral dosing.
Patle R; Shinde S; Patel S; Maheshwari R; Jariyal H; Srivastava A; Chauhan N; Globisch C; Jain A; Tekade RK; Shard A
Bioorg Med Chem Lett; 2021 Jun; 42():128062. PubMed ID: 33901643
[TBL] [Abstract][Full Text] [Related]
19. Interdependence of GLO I and PKM2 in the Metabolic shift to escape apoptosis in GLO I-dependent cancer cells.
Shimada N; Takasawa R; Tanuma SI
Arch Biochem Biophys; 2018 Jan; 638():1-7. PubMed ID: 29225125
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antitumor activity of novel 2, 3-didithiocarbamate substituted naphthoquinones as inhibitors of pyruvate kinase M2 isoform.
Ning X; Qi H; Li R; Jin Y; McNutt MA; Yin Y
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):126-129. PubMed ID: 29185365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
